Immunovant, Inc. IMVT EBITDA
Discontinued — last reported Q4 '26
EBITDA at other companies
Other financials
Where this comes from
Calculated from Immunovant, Inc.’s reported figures.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s EBITDA?
- Immunovant, Inc. (IMVT) reported EBITDA of -$142.55M in Q1 2026.
- How has Immunovant, Inc.'s EBITDA changed year-over-year?
- Immunovant, Inc.'s EBITDA decreased by 44.2% year-over-year, from -$98.87M to -$142.55M.
- What is the long-term trend for Immunovant, Inc.'s EBITDA?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EBITDA has grown at a 32.3% compound annual growth rate (CAGR), from -$156.69M to -$479.65M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.